Jyong Biotech (MENS) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Jyong Biotech (MENS) over the past year, losing 50.7% versus a loss of 95.9%. Jyong Biotech is the larger company by market cap ($156.6 million vs $152.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | TLSA |
|---|---|---|
| Share price | $2.06 | $1.20 |
| Market cap | $156.62M | $152.71M |
| 1-day change | -1.90% | +6.19% |
| YTD return | -46.84% | -24.16% |
| 1-year return | -95.89% | -50.66% |
| 5-year return | — | -25.17% |
| EPS (TTM) | $-0.06 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $2.25 |
| 52-week low | $1.43 | $0.76 |
| Distance from 52-week high | -96.73% | -46.67% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +565.00% |
| Average volume | 45.62K | 720.16K |
| Shares outstanding | 74.23M | 127.26M |
| Employees | 27 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed MENS by 45.2 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
MENS vs TLSA FAQ
Which is bigger, Jyong Biotech or Tiziana Life Sciences?
Jyong Biotech (MENS) is larger, with a market capitalization of $156.62M compared with $152.71M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, MENS or TLSA?
TLSA returned -50.66% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.